Outlook Therapeutics is a specialized biotech focused on eye disease treatments, aiming to become a significant player in conditions like wet macular degeneration, similar to how Regeneron developed Eylea for that very market.

Outlook Therapeutics is a biotech company specializing exclusively in developing drugs for eye diseases, much like how Gilead Sciences gained prominence by focusing intensely on breakthrough therapies for infectious diseases.

• ONS-5010: An ophthalmic formulation of bevacizumab in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

1. Pharmaceutical distributors and wholesalers that facilitate the supply of medicines to pharmacies, hospitals, and clinics.
2. Hospitals, ophthalmology clinics, and other healthcare providers that would administer the treatment to patients.
3. Potentially, specialty pharmacies that dispense complex or high-cost medications directly to patients.

• Wacker Biotech GmbH (subsidiary of Evonik Industries AG - EVK)
• Avara Pharmaceutical Services, Inc.

Bob Jahr

Lawrence A. Kenyon

Joel Prieve

Dr. Jennifer M. Kissner Ph.D.

1. Regulatory Approval Uncertainty for ONS-5010: Outlook Therapeutics faces substantial risk regarding the regulatory approval of its lead product candidate, ONS-5010 (LYTENAVA), for wet age-related macular degeneration (wet AMD) in the United States. The U.S. Food and Drug Administration (FDA) has issued multiple Complete Response Letters (CRLs) for ONS-5010's Biologics License Application (BLA), most recently citing a "lack of substantial evidence of effectiveness." While one pivotal study (NORSE TWO) demonstrated efficacy, another confirmatory trial (NORSE EIGHT) failed to meet its primary efficacy endpoint. The FDA continues to request additional confirmatory evidence without specifying the acceptable format, leading to significant uncertainty regarding the approval pathway and timing.
2. Significant Financial Challenges: The company is facing severe financial difficulties, characterized by negative operating and net margins, substantial operating losses, and negative cash flow. Its total liabilities outweigh total assets, and a distressed Altman Z-Score indicates a high risk of bankruptcy. The ongoing delays in regulatory approval for ONS-5010 exacerbate these financial pressures, as the company incurs considerable research and development and operational costs without a significant revenue stream from its primary product in the U.S. market.
3. Reliance on Third-Party Manufacturing: Outlook Therapeutics is highly dependent on third-party manufacturers, notably FUJIFILM Diosynth Biotechnologies, for the production and supply of its drug candidates, including ONS-5010. This reliance exposes the company to risks such as potential supply interruptions, quality control issues, and challenges with regulatory compliance. Any disruptions or breaches in these manufacturing agreements could lead to costly delays in clinical trials and commercialization efforts, negatively impacting business operations, revenue, and gross margins.

The addressable markets for Outlook Therapeutics' main product candidate, ONS-5010, which targets wet age-related macular degeneration (wet AMD) and other retina diseases, are substantial globally and within key regions.

Wet Age-Related Macular Degeneration (wet AMD)

• Globally, the wet AMD market size was estimated at USD 10.6 billion in 2025 and is projected to grow to USD 16.7 billion by 2032.
• In the 7 Major Markets (7MM), which include the U.S., Germany, France, Italy, Spain, the United Kingdom, and Japan, the wet AMD market was valued at approximately USD 7.783 billion in 2023.
• Specifically for the U.S. market, the wet AMD market size was approximately USD 2.599 billion in 2023 and is expected to increase at a Compound Annual Growth Rate (CAGR) of 6.6% by 2034.

Broader Retinal Disease Therapeutics Market (including wet AMD and other retina diseases)

• The global retinal disease therapeutics market was valued at USD 12.86 billion in 2024 and is anticipated to grow to USD 27.93 billion by 2033, with a CAGR of 9%.
• The U.S. retinal disorder treatment market is projected to expand from USD 7.1 billion in 2024 to USD 13.1 billion by 2034.
• Outlook Therapeutics itself has stated that ONS-5010 has the potential to address a USD 9.1 billion anti-VEGF market. The macular degeneration segment holds the largest share within the overall retinal disorder treatment market.

Outlook Therapeutics (OTLK) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily centered around its lead product candidate, ONS-5010 (branded as LYTENAVA).

1. Growing Sales and Market Uptake in Existing European Markets: LYTENAVA (bevacizumab gamma) has already received marketing authorization from the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of wet age-related macular degeneration (wet AMD). Commercialization commenced in June 2025, with initial sales in Germany and the UK. The company has observed strong positive momentum, evidenced by a doubling of Lytenava unit sales in the UK and Germany in the first quarter of 2026 compared to the prior quarter, indicating increasing market uptake. Continued growth in these initial markets is expected to contribute to revenue.
2. Geographic Expansion into Additional European Markets: Beyond the UK and Germany, Outlook Therapeutics plans to expand the launch of LYTENAVA into other key European markets. The anticipated launch in additional EU markets, such as France, Italy, and Spain, by 2027 is expected to further drive revenue growth. The company also continues to identify potential partners for additional expansion outside the U.S., with efforts to expand into Austria and the Netherlands already underway.
3. Potential U.S. FDA Approval and Commercial Launch of ONS-5010: While ONS-5010 has faced multiple Complete Response Letters (CRLs) from the FDA regarding its Biologics License Application (BLA) for wet AMD, most recently on December 31, 2025, Outlook Therapeutics remains committed to securing U.S. approval. The company views the U.S. as the largest addressable market for anti-VEGF therapies, with an estimated annual revenue of approximately $6.7 billion across wet AMD, DME, and RVO treatments. An eventual FDA approval would allow ONS-5010 (Lytenava) to become the first officially sanctioned ophthalmic bevacizumab in the U.S., unlocking significant revenue potential and providing 12 years of regulatory exclusivity.
4. Conversion from Off-Label Bevacizumab Use: If ONS-5010 receives FDA approval, it is poised to capture a considerable patient share from the current off-label use of Avastin (bevacizumab) for wet AMD. As an FDA-approved, on-label formulation specifically for ophthalmic use, ONS-5010 offers a safer and more consistent alternative to compounded Avastin, potentially attracting both physicians and patients. Analysts anticipate substantial long-term growth prospects from converting off-label bevacizumab use to an approved product.

Share Issuance

• The number of shares outstanding for Outlook Therapeutics increased by 105.06% in one year.
• The company executed a 1-for-20 reverse stock split on March 14, 2024.
• Institutional investors hold a total of 6,902,013 shares in the company.

Inbound Investments

• Sphera-affiliated investment entities reported beneficial ownership of 3,153,856 warrants as of December 16, 2025, each exercisable into one share of common stock, representing 4.69% of the class.
• In February 2026, Outlook Therapeutics expanded its European presence through an exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland.

Capital Expenditures

• Outlook Therapeutics reported $0.00 in capital expenditures during the last 12 months.
• The company's capital allocation is primarily focused on research and development for its lead product candidate, ONS-5010, for ophthalmic indications, which are generally expensed rather than capitalized.